What Argenx Doubters Overlooked

If you only glanced at the headlines this year, argenx looked like a tug of war between upbeat Vyvgart data, acquisitions, and worries about pricing pressure and trial risk. Holding argenx from the start of the year would have returned 20.9%, including dividends. If you had been deciding on 1 January whether to buy into that mix of promise and concentration risk, what exactly in the record back then justified taking the ride that followed?

The useful thing about a Narrative is that the reasoning is checkable: the assumptions sit beside the argument, and together they imply an estimated Fair Value you can disagree with.

The easy part of this move is behind argenx. Zero in on 201 high quality undervalued stocks for companies trading below our estimates.

The Two argenx Stories Investors Had To Weigh

The shares cost €717 at the start of the period, and investors in argenx had to decide which of two very different stories felt more believable.

On the upbeat side, the narrative titled “AI Collaboration And Aging Trends Will Expand Autoimmune Biologics Markets” put Fair Value at €885, assuming revenue growth of 35.9% a year and profit margins rising to 53.9% within roughly three years.

The opposing view, “Rising Pricing Pressures And Biosimilar Challenges Will Weaken Margins,” set Fair Value at €528, with revenue growth of 24.2% and margins declining to 26.8% as pricing and biosimilar risks built up.

What The Results Said About The Two argenx Cases

The key development was argenx broadening Vyvgart’s label across all generalized myasthenia gravis serotypes and advancing it in autoimmune myositis, which supported the upbeat case that framed Vyvgart as a multi indication franchise. At the same time, revenue and profit rose between Q3 2025 and Q3 2026 while net margin slipped from 29.9% to 28.9%, which kept the cautious pricing pressure story alive. Overall, the evidence cut both ways.

The hinge assumption here was not just growth, but how much of that extra top line turned into richer earnings per dollar of sales. For any future biotech you look at, track revenue, absolute profit and the stated net margin side by side each year to see whether new indications are scaling profitably or simply stretching the commercial footprint.

What argenx's Current Price Already Assumes

argenx now trades at €875, up 20.9% from the start of the year, and the current Narrative’s Fair Value view sits below that level rather than above it.

According to kapirey, an investor in the Simply Wall St Community who wrote the Narrative, the bullish story leans heavily on VYVGART plus a busy late stage pipeline, while the concerns focus on pricing power and reliance on one franchise. A buyer today is effectively assuming VYVGART can support broader earnings over time, so how do the single product, pricing and regulatory risks in the Narrative weigh on that bet?

"Bull Case: Strong, proven revenue growth. Scalable platform across indications. Pipeline with multiple catalysts. Leadership in a novel therapeutic class. Bear Case: High dependence on one product. Pricing and regulatory pressure may erode margins. High pipeline risk (typical biotech). Increasing competition."

That disagreement has a full argument behind it. → Uncover the lower Fair Value this Narrative argues for

Which Company Could Surprise You Next?

The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?

• Company 1 - 39% below our estimate - builds a dense nutrition lineup across packaged categories and multi-channel distribution points.
• Company 2 - 31% below our estimate - expands a significant gold resource inventory while optimizing higher-cost operations in volatile jurisdictions.
• Company 3 - 46% below our estimate - supplies full-stack accelerated computing hardware that underpins large-scale artificial intelligence infrastructure deployments.

Three companies from the same screener. Open the full list of 194 financially solid companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com